Last $16.80 USD
Change Today +0.12 / 0.72%
Volume 202.4K
VIVO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Open
$16.76
Previous Close
$16.68
Day High
$16.91
Day Low
$16.70
52 Week High
01/10/14 - $27.72
52 Week Low
11/21/14 - $15.80
Market Cap
700.0M
Average Volume 10 Days
282.2K
EPS TTM
$0.83
Shares Outstanding
41.7M
EX-Date
11/13/14
P/E TM
20.2x
Dividend
$0.80
Dividend Yield
4.76%
Current Stock Chart for MERIDIAN BIOSCIENCE INC (VIVO)

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

550 Employees
Last Reported Date: 12/1/14
Founded in 1976

meridian bioscience inc (VIVO) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $602.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $263.3K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $356.7K
Executive Vice President and President of Mer...
Total Annual Compensation: $307.0K
Compensation as of Fiscal Year 2014.

meridian bioscience inc (VIVO) Key Developments

Meridian Bioscience Receives Contract

Meridian Bioscience has been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding will be provided through a Small Business Innovation Research (SBIR) contract. The contract follows an initial contract awarded to the company in 2013 and will fund a 15-month research and development effort leading to scale up and manufacture of a rotavirus vaccine for use in clinical trials.

Meridian Bioscience, Inc. Declares Regular Cash Dividend for the Fourth Quarter Ended September 30, 2014 Payable on November 28, 2014; Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014 Reaffirms Earnings Guidance for the Fiscal Year Ending September 30, 2015

Meridian Bioscience, Inc.'s Board of Directors declared the regular quarterly cash dividend of $0.20 per share for the fourth quarter ended September 30, 2014. The dividend is of record November 17, 2014 and payable November 28, 2014. The company reported unaudited earnings results for the fourth quarter and full year ended September 30, 2014. For the quarter, the company's net revenues were $46,692,000 compared to $48,962,000 a year ago. Operating income was $11,968,000 compared to $13,271,000 a year ago. Earnings before income taxes was $12,174,000 compared to $13,056,000 a year ago. Net earnings was $8,182,000 compared to $9,150,000 a year ago. Net earnings per diluted common share was $0.20 compared to $0.22 a year ago. Net earnings declined by 11%, primarily due to lower overhead absorption, specific price pressure in the Diagnostics segment, one-time charges of $817,000 ($546,000 after taxes) incurred due to compensation-related expenses associated with the recent death of Meridian's founder, Bill Motto, and inventory write-offs from unused and expiring clinical trial materials. For the full year, the company's net Revenue was $188,832,000 compared to $188,686,000 a year ago. Operating income was $52,392,000 compared to $57,314,000 a year ago. Earnings before income taxes was $52,108,000 compared to $57,362,000 a year ago. Net earnings was $34,743,000 compared to $38,032,000 a year ago. Net earnings per diluted common share was $0.83 compared to $0.91 a year ago. The company reaffirmed earnings guidance for the fiscal year ending September 30, 2015. The management expects net revenues to be in the range of $193 million to $200 million and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 41.9 million at fiscal 2014 year end to approximately 42.4 million at fiscal 2015 year end. The revenue and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any additional acquisitions the Company might complete during fiscal 2015.

Meridian Bioscience, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 08:30 AM

Meridian Bioscience, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 08:30 AM. Venue: The Westin Grand Central, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $16.80 USD +0.12

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $2.89 USD +0.08
Great Basin Scientific Inc $2.35 USD -0.18
Luminex Corp $18.99 USD +0.39
Nanosphere Inc $0.40 USD +0.01
Quidel Corp $27.78 USD -0.08
View Industry Companies
 

Industry Analysis

VIVO

Industry Average

Valuation VIVO Industry Range
Price/Earnings 20.3x
Price/Sales 3.7x
Price/Book 4.3x
Price/Cash Flow 20.1x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDIAN BIOSCIENCE INC, please visit www.meridianbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.